Gabapentin (Epilepsy)

Preterm (< 37 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7416
R21830		 Miškov (Gabapentin) (Controls exposed to Lamotrigine, sick), 2016 Premature deliveries during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 12.00 [0.53;273.05] C
excluded (control group) 		1/2   2/26 3 2
ref
S7048
R19902		 Miškov (Gabapentin) (Controls unexposed, disease free), 2016 Premature deliveries during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No 31.00 [1.63;589.49] C
excluded (control group) 		1/2   4/128 5 2
ref
S7410
R21802		 Miškov (Gabapentin) (Controls unexposed, sick), 2016 Premature deliveries during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 21.00 [0.27;1646.32] C 1/2   0/4 1 2
ref
S6252
R16648		 Arkilo (Gabapentin), 2015 Premature delivery during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick Adjustment: No 5.86 [0.10;346.64] C 0/1   3/24 3 1
ref
Total 2 studies 10.63 [0.54;209.24] 4 3
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Miškov (Gabapentin) (Controls unexposed, sick), 2016Miškov, 2016 1 21.00[0.27; 1646.32]1247%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: moderateROB reporting: moderate Arkilo (Gabapentin), 2015Arkilo, 2015 2 5.86[0.10; 346.64]3153%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 10.63[0.54; 209.24]430.950.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Gabapentin) (Controls unexposed, sick; 2: Gabapentin;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 10.63[0.54; 209.24]430%NAMiškov (Gabapentin) (Controls unexposed, sick), 2016 Arkilo (Gabapentin), 2015 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 21.00[0.27; 1646.32]12 -NAMiškov (Gabapentin) (Controls unexposed, sick), 2016 1 exposed to other treatment, sickexposed to other treatment, sick 5.86[0.10; 346.64]31 -NAArkilo (Gabapentin), 2015 1 Tags Adjustment   - No  - No 10.63[0.54; 209.24]430%NAMiškov (Gabapentin) (Controls unexposed, sick), 2016 Arkilo (Gabapentin), 2015 2 All studiesAll studies 10.63[0.54; 209.24]430%NAMiškov (Gabapentin) (Controls unexposed, sick), 2016 Arkilo (Gabapentin), 2015 20.550.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 7416, 7048

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale31.00[1.63; 589.49]52 -NAMiškov (Gabapentin) (Controls unexposed, disease free), 2016 1 unexposed, sick controlsunexposed, sick controls Out of scale21.00[0.27; 1646.32]12 -NAMiškov (Gabapentin) (Controls unexposed, sick), 2016 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 9.21[0.77; 110.02]630%NAMiškov (Gabapentin) (Controls exposed to Lamotrigine, sick), 2016 Arkilo (Gabapentin), 2015 20.510.01.0